Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Friday. The brokerage issued a sell rating on the stock.

Other analysts have also recently issued reports about the company. Robert W. Baird restated a neutral rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. William Blair reaffirmed a market perform rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada reiterated a sector perform rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a research report on Friday, June 28th. Finally, Baird R W lowered Catalent from a strong-buy rating to a hold rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Hold and a consensus target price of $59.83.

Catalent Price Performance

NYSE CTLT opened at $60.61 on Friday. The firm’s 50 day moving average price is $59.93 and its 200-day moving average price is $57.53. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The company has a market cap of $10.97 billion, a PE ratio of -9.94, a P/E/G ratio of 2.32 and a beta of 1.15. Catalent has a 52-week low of $31.80 and a 52-week high of $61.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Sell-side analysts forecast that Catalent will post 0.85 EPS for the current fiscal year.

Insider Activity at Catalent

In other news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,410 shares of company stock worth $732,680. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its stake in Catalent by 26.9% in the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after purchasing an additional 278 shares in the last quarter. Czech National Bank raised its holdings in Catalent by 6.9% in the 3rd quarter. Czech National Bank now owns 36,867 shares of the company’s stock valued at $2,233,000 after acquiring an additional 2,380 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Catalent by 19.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 48,900 shares of the company’s stock valued at $2,962,000 after purchasing an additional 7,800 shares during the period. AMF Tjanstepension AB bought a new stake in shares of Catalent in the 3rd quarter valued at approximately $3,027,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Catalent during the 2nd quarter worth approximately $29,172,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.